Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine‐maintained intravenous heroin abusers
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background Sublingual buprenorphine is an effective maintenance treatment for opioid dependence, yet intravenous buprenorphine misuse occurs. A buprenorphine/naloxone formulation was developed to mitigate this misuse risk. This randomized, double‐blind, cross‐over study was conducted to assess the intravenous abuse potential of buprenorphine/naloxone compared with buprenorphine in buprenorphine‐maintained injection drug users (IDUs). Methods Intravenous heroin users (n = 12) lived in the hospital for 8–9 weeks and were maintained on each of three different sublingual buprenorphine doses (2 mg, 8 mg, 24 mg). Under each maintenance dose, participants completed laboratory sessions during which the reinforcing and subjective effects of intravenous placebo, naloxone, heroin and low and high doses of buprenorphine and buprenorphine/naloxone were examined. Every participant received each test dose under the three buprenorphine maintenance dose conditions. Results Intravenous buprenorphine/naloxone was self‐administered less frequently than buprenorphine or heroin (P < 0.0005). Participants were most likely to self‐administer drug intravenously when maintained on the lowest sublingual buprenorphine dose. Subjective ratings of ‘drug liking’ and ‘desire to take the drug again’ were lower for buprenorphine/naloxone than for buprenorphine or heroin (P = 0.0001). Participants reported that they would pay significantly less money for buprenorphine/naloxone than for buprenorphine or heroin (P < 0.05). Seven adverse events were reported; most were mild and transient. Conclusions These data suggest that although the buprenorphine/naloxone combination has intravenous abuse potential, that potential is lower than it is for buprenorphine alone, particularly when participants received higher maintenance doses and lower buprenorphine/naloxone challenge doses. Buprenorphine/naloxone may be a reasonable option for managing the risk for buprenorphine misuse during opioid dependence treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Comparison of Levomethadyl Acetate, Buprenorphine, and Methadone for Opioid Dependence
Johnson, R. E., Chutuape, M. A., Strain, E. C., Walsh, S. L., Stitzer, M. L., & Bigelow, G. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431802 · Cited by 623
Fudala, P. J., Bridge, T. P., Herbert, S., Williford, W. O., Chiang, C. N., Jones, K., Collins, J., Raisch, D., Casadonte, P., Goldsmith, R. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022164 · Cited by 577 · cited 1×
“When taken sublingually as prescribed, its therapeutic efficacy and safety are similar to those of buprenorphine alone [15].”
BackgroundBuprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Kimber, J., Breen, C., & Davoli, M. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub3 · Cited by 501
Counseling plus Buprenorphine–Naloxone Maintenance Therapy for Opioid Dependence
Fiellin, D. A., Pantalon, M. V., Chawarski, M. C., Moore, B. A., Sullivan, L. E., O'Connor, P. G., & Schottenfeld, R. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055255 · Cited by 351
Clinical efficacy of buprenorphine: comparisons to methadone and placebo
LING, W. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(03)00059-0 · Cited by 121
Gossop, M., Marsden, J., Stewart, D., & Treacy, S. (2002) · AIDS Care · doi:10.1080/09540120220097955 · Cited by 78
Cited by
Maintenance Medication for Opiate Addiction: The Foundation of Recovery
Bart, G. (2012) · Journal of Addictive Diseases · doi:10.1080/10550887.2012.694598 · Cited by 461
Buprenorphine Pharmacology Review: Update on Transmucosal and Long-acting Formulations
Coe, M. A., Lofwall, M. R., & Walsh, S. L. (2019) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000457 · Cited by 173
“Laboratory studies reliably report reduced abuse liability of buprenorphine/naloxone compared with buprenorphine alone (Comer and Collins, 2002; Comer et al., 2010; Middleton et al., 2011; Walsh et al., 2016).”
Middleton, L. S., Nuzzo, P. A., Lofwall, M. R., Moody, D. E., & Walsh, S. L. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03424.x · Cited by 77
Noble, F., & Marie, N. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00742 · Cited by 56
“Human studies shown that it has a reduced abuse potential (69), however recent preclinical (70) and clinical (71, 72) data questioned the lower level of rewarding properties of intravenous suboxone.”
BackgroundGroup-based treatment of opioid use disorder with buprenorphine: A systematic review
Sokol, R., LaVertu, A. E., Morrill, D., Albanese, C., & Schuman-Olivier, Z. (2018) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2017.11.003 · Cited by 50
Metadata
- Authors
- Comer, S. D., Sullivan, M. A., Vosburg, S. K., Manubay, J., Amass, L., Cooper, Z. D., Saccone, P., & Kleber, H. D.
- Venue
- Addiction
- Publisher
- Wiley
- Published
- 2010-03-10
- Volume
- 105
- Issue
- 4
- Pages
- 709-718
- ISSN
- 0965-2140 (ISSN-L)
- 1360-0443
- OpenAlex
- W1923689435
- Cited by
- 104
- References
- 6
- FWCI
- 8.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine‐maintained intravenous heroin abusers. https://app.cochat.ai/papers/10.1111/j.1360-0443.2009.02843.x
- The paper
- Comer, S. D., Sullivan, M. A., Vosburg, S. K., Manubay, J., Amass, L., Cooper, Z. D., Saccone, P., & Kleber, H. D. (2010). Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine‐maintained intravenous heroin abusers. Addiction. https://doi.org/10.1111/j.1360-0443.2009.02843.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.